Summit Therapeutics Stock (NASDAQ:SMMT)
Previous Close
$18.99
52W Range
$1.64 - $33.89
50D Avg
$19.96
200D Avg
$9.63
Market Cap
$14.71B
Avg Vol (3M)
$5.15M
Beta
-0.97
Div Yield
-
SMMT Company Profile
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
SMMT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| KRON | Kronos Bio, Inc. |
| NKTX | Nkarta, Inc. |
| OCEA | Ocean Biomedical, Inc. |
| SONN | Sonnet BioTherapeutics Holdings, Inc. |
| KZR | Kezar Life Sciences, Inc. |
| ZURA | Zura Bio Limited |
| ELEV | Elevation Oncology, Inc. |
| CDIO | Cardio Diagnostics Holdings, Inc. |
| ATNF | 180 Life Sciences Corp. |